Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
FranceIPO:
10 July 2020Website:
http://www.inventivapharma.comNext earnings report:
25 September 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
IVA Latest News
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Daix (France), Long Island City (New York, United States), May 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), also known as non-alcoholic steatohepatitis (“NASH”), and other diseases with significant unmet medical needs, today announced that two scientific abstracts have been selected for poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver (EASL) on June 5-8, 2024 in Milan, Italy.
Daix (France), Long Island City (New York, United States), March 13, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, and other diseases with significant unmet medical needs, will hold an investor conference on Tuesday, March 19 , to share the results of the LEGEND Phase II trial, a placebo-controlled, study evaluating lanifibranor alone and in combination with the SGLT2 inhibitor empagliflozin in patients with MASH/NASH and type 2 diabetes (T2D).
IVA has robust data from a mid-stage NASH trial. They have an ongoing pivotal study running, to topline in H2 2025. They don't have enough cash to complete that trial.
Inventiva S.A. (NASDAQ:IVA ) 2022 Full Year Results Earnings Conference Call March 30, 2023 8:00 AM ET Company Participants Frédéric Cren – Chief Executive Officer Jean Volatier – Chief Financial Officer Michael Cooreman – Chief Medical Officer Conference Call Participants Seamus Fernandez – Guggenheim Securities Annabel Samimy – Stifel Ed Arce – H.C.
What type of business is Inventiva SA?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
What sector is Inventiva SA in?
Inventiva SA is in the Healthcare sector
What industry is Inventiva SA in?
Inventiva SA is in the Biotechnology industry
What country is Inventiva SA from?
Inventiva SA is headquartered in France
When did Inventiva SA go public?
Inventiva SA initial public offering (IPO) was on 10 July 2020
What is Inventiva SA website?
https://www.inventivapharma.com
Is Inventiva SA in the S&P 500?
No, Inventiva SA is not included in the S&P 500 index
Is Inventiva SA in the NASDAQ 100?
No, Inventiva SA is not included in the NASDAQ 100 index
Is Inventiva SA in the Dow Jones?
No, Inventiva SA is not included in the Dow Jones index
When does Inventiva SA report earnings?
The next expected earnings date for Inventiva SA is 25 September 2024